Trial Search Results

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Drug: Cyclophosphamide
  • Drug: Etoposide
  • Drug: Melphalan
  • Drug: Carmustine
  • Drug: Filgrastim


Phase 2



   - Stage II to III multiple myeloma, or progression after initial treatment of Stage I
   disease; early or relapsed

   - Age 18 to 75 years.

   - Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

   - Patients with amyloidosis may be eligible for this trial, with approval by the
   Principle Investigator.

   - Patients must have a Karnofsky performance status > 70%.

   - Aspartate aminotransferase (AST) must be < 2 x upper limit of normal (ULN)

   - Alanine aminotransferase (ALT) must be < 2 x ULN

   - Total bilirubin < 2 mg/dL.

   - Serum creatinine < 2.0 or 24-hour creatinine clearance ≥ 60 mL/min.

   - Patients must be HIV-negative.

   - Patients must provide signed, informed consent.


   - Severe psychological or medical illness

   - Prior autologous hematopoietic cell transplantation

   - Pregnant

   - Lactating women

   - Smoldering multiple myeloma,

   - Monoclonal gammopathy of unknown significance or primary amyloidosis will be excluded
   from this study

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting